Exelixis, Inc. v. Intas Pharmaceuticals Ltd.
Exelixis v. Intas: The Patent Fight Behind a Multibillion-Dollar Oncology Play
If you think generic competition is the biggest threat to blockbuster oncology drugs, think again. The real battlefield is often the patent landscapeand the next round of le…
